NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

GLTO

Galecto Inc

Apr 25 • 02:01PM ET

2.86

Dollar change +0.01
Percentage change 0.34	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN VRTX NBIX IONS ARWR FGEN ASND XENE RDUS AKRO

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-18.59	Insider Own	13.48%	Shs Outstand	1.32M	Perf Week	17.69%
Market Cap	3.78M	Forward P/E	-	EPS next Y	-19.47	Insider Trans	-1.15%	Shs Float	1.14M	Perf Month	-27.42%
Income	-21.44M	PEG	-	EPS next Q	-	Inst Own	3.19%	Short Float	5.67%	Perf Quarter	-49.14%
Sales	0.00M	P/S	-	EPS this Y	21.75%	Inst Trans	11.40%	Short Ratio	0.26	Perf Half Y	-58.31%
Book/sh	10.99	P/B	0.26	EPS next Y	-34.28%	ROA	-77.45%	Short Interest	0.06M	Perf Year	-83.67%
Cash/sh	10.72	P/C	0.27	EPS next 5Y	-17.40%	ROE	-91.62%	52W Range	2.01 - 18.50	Perf YTD	-38.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	14.83%	ROI	-134.90%	52W High	-84.54%	Beta	1.28
Dividend TTM	-	Quick Ratio	14.07	Sales past 5Y	0.00%	Gross Margin	-	52W Low	42.28%	ATR (14)	0.40
Dividend Ex-Date	-	Current Ratio	14.07	EPS Y/Y TTM	48.81%	Oper. Margin	-	RSI (14)	46.42	Volatility	7.76% 13.79%
Employees	5	Debt/Eq	0.10	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	8.00
Option/Short	No / Yes	LT Debt/Eq	0.10	EPS Q/Q	12.50%	Payout	-	Rel Volume	0.21	Prev Close	2.85
Sales Surprise	-	EPS Surprise	-72.73%	Sales Q/Q	-	Earnings	Mar 19 AMC	Avg Volume	247.49K	Price	2.86
SMA20	7.57%	SMA50	-23.20%	SMA200	-62.11%	Trades		Volume	39,190	Change	0.34%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-26-21	Resumed	Credit Suisse	Outperform	$12
Nov-23-20	Initiated	SVB Leerink	Outperform	$27
Nov-23-20	Initiated	Credit Suisse	Outperform	$29
Nov-23-20	Initiated	BofA Securities	Buy	$21

Mar-19-25 04:45PM	Galecto Reports Full-Year 2024 Financial Results (GlobeNewswire)
Feb-06-25 08:00AM	Galecto to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-14-24 09:55AM	Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-01-24 08:30AM	Galecto Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-18-24 08:15AM	Galecto price target raised to $10 from $9 at Oppenheimer (TipRanks) +5.79%
08:30AM	Loading…
Oct-15-24 08:30AM	Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler (GlobeNewswire)
Oct-07-24 08:45AM	Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines (GlobeNewswire) -27.53%
Aug-28-24 09:00AM	Galecto Announces Reverse Stock Split (GlobeNewswire) -6.59%
Aug-12-24 10:53PM	GLTO Stock Earnings: Galecto Beats EPS for Q2 2024 (InvestorPlace) +6.26%
May-03-24 10:54AM	GLTO Stock Earnings: Galecto Beats EPS for Q1 2024 (InvestorPlace)
May-01-24 04:01PM	Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab (GlobeNewswire) +5.43%
Mar-15-24 01:53PM	GLTO Stock Earnings: Galecto Beats EPS for Q4 2023 (InvestorPlace) +5.30%
Feb-14-24 12:00PM	Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +11.93%
Jan-09-24 04:57PM	What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock (Zacks)
Dec-22-23 06:52AM	Galecto posts myelofibrosis data as search for savior continues, investors shrug (FierceBiotech.com)
04:05PM	Loading…
Dec-21-23 04:05PM	Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis (GlobeNewswire)
Oct-23-23 08:00AM	Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial (GlobeNewswire)
Sep-28-23 09:49AM	Spotify downgraded, Tractor Supply upgraded: Wall Street's top analyst calls (The Fly)
Sep-27-23 05:08AM	Galecto lays off 70%, hunts for 'strategic alternatives' in wake of fibrosis drug fail (FierceBiotech.com) +22.24%
Sep-26-23 04:01PM	Galecto Announces Plans to Explore Strategic Alternatives (GlobeNewswire)
Aug-31-23 11:00AM	Galecto to Present at Investor Conferences in September (GlobeNewswire)
Aug-17-23 07:01PM	OrbiMed Advisors LLC Reduces Stake in Galecto Inc (GuruFocus.com) -7.34%
08:58AM	Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More (Zacks)
Aug-16-23 07:46AM	Galecto (GLTO) Down 71% as Lung Disease Candidate Fails (Zacks)
Aug-15-23 07:35AM	Galecto to discontinue development of lung disease treatment (Reuters) -71.22%
07:30AM	Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jul-31-23 04:05PM	Galecto Reports Second Quarter Operating and Financial Results (GlobeNewswire) -9.09%
Jul-27-23 11:02PM	ORBIMED ADVISORS LLC Reduces Stake in Galecto Inc (GuruFocus.com)
Jul-25-23 09:59AM	These 2 Strong Buy Penny Stocks Could Go Boom, Say Analysts (TipRanks) +29.79%
Jun-20-23 08:58AM	Galecto Set to Join Russell Microcap® Index (GlobeNewswire)
08:00AM	Loading…
May-30-23 08:00AM	Galecto to Present at the Upcoming Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 08:30AM	Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
May-20-23 08:54AM	Companies Like Galecto (NASDAQ:GLTO) Could Be Quite Risky (Simply Wall St.)
May-17-23 04:01PM	Galecto to Present Poster at Upcoming ATS 2023 International Conference (GlobeNewswire) +5.86%
Apr-28-23 08:00AM	Galecto Reports First Quarter Operating and Financial Results (GlobeNewswire)
Apr-13-23 08:30AM	Galecto to Present Two Posters at AACR Annual Meeting 2023 (GlobeNewswire)
Mar-09-23 07:00AM	Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022 (GlobeNewswire) -8.13%
Mar-02-23 04:05PM	Galecto to Participate in Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-01-23 08:00AM	Galecto to Participate in SVB Securities Global Biopharma Conference (GlobeNewswire) +5.65%
Dec-11-22 07:36AM	Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-07-22 04:05PM	Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-24-22 09:55AM	Galecto, Inc. (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-11-22 12:00PM	All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy (Zacks)
Nov-08-22 09:15AM	Galecto Reports Third Quarter Operating and Financial Results (GlobeNewswire) -7.35%
06:00AM	Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients (GlobeNewswire)
Nov-03-22 08:00AM	Galecto to Participate in Jefferies London Healthcare Conference (GlobeNewswire) +20.01%
Oct-31-22 08:00AM	Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLDs The Liver Meeting® 2022 (GlobeNewswire) +6.35%
Oct-19-22 08:00AM	Galectos Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute (GlobeNewswire)
Oct-17-22 06:00AM	Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022 (GlobeNewswire)
Sep-29-22 11:17AM	Galecto's Myelofibrosis Candidate Reduces Bone Marrow Fibrosis (Benzinga) -22.08%
06:00AM	GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target (GlobeNewswire)
Sep-06-22 08:30AM	Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-29-22 08:30AM	Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal (GlobeNewswire)
Jul-29-22 09:00AM	Galecto Reports Second Quarter Operating and Financial Results (GlobeNewswire)
Jul-03-22 08:17AM	Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely? (Simply Wall St.)
Jun-16-22 08:00AM	Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC (GlobeNewswire)
May-31-22 08:30AM	Galecto to Participate at Jefferies Healthcare Conference (GlobeNewswire)
May-26-22 08:30AM	Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting (GlobeNewswire)
May-02-22 08:30AM	Galecto to Participate at Upcoming Investor Conferences (GlobeNewswire)
Apr-29-22 08:57AM	Galecto Reports First Quarter Operating and Financial Results (GlobeNewswire)
Apr-26-22 08:30AM	Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF (GlobeNewswire) -7.94%
Mar-29-22 08:30AM	Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis (GlobeNewswire)
Mar-25-22 10:25AM	UnitedHealth (UNH) Arm Optum Acquires Refresh Mental Health (Zacks)
Mar-15-22 11:10AM	Ensign Group (ENSG) Up 9.9% in 3 Months: More Room to Grow? (Zacks)
Mar-10-22 11:05AM	Here's Why You Should Retain Community Health (CYH) Stock (Zacks)
Mar-09-22 10:49AM	Anthem (ANTM) Rises 3.7% Since Q4 Earnings, Reiterates View (Zacks) +7.49%
Mar-04-22 10:00AM	Galecto, Inc. (GLTO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Feb-17-22 05:00PM	Galecto Reports Financial Results for the Year Ended December 31, 2021 (GlobeNewswire) -5.48% -5.29%
Feb-07-22 08:00AM	Galecto to Participate at Upcoming Investor Conferences (GlobeNewswire)
Jan-27-22 07:00AM	Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care (GlobeNewswire)
Jan-24-22 05:56AM	Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth? (Simply Wall St.) +6.13%
Jan-19-22 09:38PM	Marquette Asset Management, LLC Buys Vanguard Total Bond Market ETF, ARK Next Generation ... (GuruFocus.com)
Jan-05-22 08:00AM	Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer (GlobeNewswire) -8.76%
Dec-20-21 08:00AM	Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022 (GlobeNewswire)
Dec-13-21 08:00AM	Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial (GlobeNewswire)
Nov-04-21 04:30PM	Galecto Reports Third Quarter Operating and Financial Results (GlobeNewswire)
Nov-02-21 11:26AM	Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting (Benzinga)
08:00AM	Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer (GlobeNewswire)
01:14AM	Penny Stocks to Buy Using Technical Analysis for November 2021 (Investopedia)
Oct-28-21 08:00AM	Galecto Hosting a Key Opinion Leader Webinar on GB1211: A Potential Treatment For Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-26-21 08:00AM	Galecto to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-15-21 08:30AM	Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference (GlobeNewswire)
Sep-13-21 08:00AM	Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis (GlobeNewswire)
Aug-18-21 09:25AM	Galecto Starts Dosing In Mid-Stage Myelofibrosis Trial (Benzinga)
08:00AM	Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MYLOX-1 Trial) (GlobeNewswire)
Aug-05-21 08:30AM	Galecto Reports Second Quarter Operating and Financial Results (GlobeNewswire)
Jul-28-21 04:31AM	Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely? (Simply Wall St.) +5.19%
Jul-13-21 08:00AM	Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jun-22-21 12:40PM	Galecto's GB0139 Shows Favorable Safety In COVID-19 Patients, But Plans To Focus On Fibrosis, Cancer Programs (Benzinga)
09:27AM	Galectos GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients (GlobeNewswire)
Jun-10-21 03:31PM	Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times (MarketWatch) +60.00%
Jun-02-21 08:00AM	Galecto Hosting Expert Perspectives Webinar on the Current Myelofibrosis Treatment Landscape and Potential Future Treatments (GlobeNewswire)
May-11-21 08:00AM	Galecto Appoints Garrett Winslow as General Counsel (GlobeNewswire)
May-06-21 08:00AM	Galecto to Present at Upcoming Investor Conferences and Host Myelofibrosis Key Opinion Leader Event (GlobeNewswire)
May-04-21 08:30AM	Galecto Reports First Quarter Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-29-21 05:49AM	Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares? (Simply Wall St.)
Apr-19-21 06:38AM	Galecto (GLTO) Enters Oversold Territory (Zacks)
Apr-15-21 08:00AM	Galectin-3 has a key role in Gastric Cancer (GlobeNewswire)
Mar-29-21 08:30AM	Galecto Reports Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update (GlobeNewswire)
Mar-23-21 10:26AM	UPDATE: Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139 (GlobeNewswire)

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jorgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgard Schambye in 2011 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Winslow Garrett	General Counsel	Jan 03 '25	Sale	5.60	471	2,638	1,009	Jan 07 04:00 PM
Firmani Lori	Interim CFO	Jan 03 '25	Sale	5.63	261	1,469	465	Jan 07 04:00 PM
Schambye Hans T.	Chief Executive Officer	Jan 03 '25	Sale	5.60	1,341	7,510	3,397	Jan 07 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GLTO

Galecto Inc

Upgrade your FINVIZ experience